lonitoclax

Lonitoclax is a next-generation, oral, once-daily small molecule inhibitor of B-cell lymphoma-2 (BCL-2), developed for the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It is designed with best-in-class selectivity for BCL-2 over BCL-XL to mitigate the hematologic and immune toxicities observed with earlier BCL-2 inhibitors like venetoclax. Lonitoclax features a unique binding mode, shorter half-life, and reduced cytochrome P450 3A4 inhibition properties to lower risks of tumor lysis syndrome and drug accumulation. Preclinical studies have shown monotherapy activity as well as synergistic effects when combined with agents such as azacitidine, FLT3 inhibitors, or menin inhibitors. Early clinical data from Phase 1 trials in healthy volunteers demonstrated robust inhibition of BCL-2 without significant safety signals or pharmacokinetic interactions with strong CYP3A4 inhibitors[6][8].

Brand names

eiletoclax